MNLO - メンロ―・セラピュ―ティクス (Menlo Therapeutics Inc.) メンロ―・セラピュ―ティクス

 MNLOのチャート


 MNLOの企業情報

symbol MNLO
会社名 Menlo Therapeutics Inc (メンロ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メンロ・セラピューティクス(Menlo Therapeutics Inc.)は生物医薬品会社である。同社はアトピー性皮膚炎、乾癬、掻痒症などの皮膚疾患に関連する痒みの治療用セロピタントの開発と製品化に注力する。同社はまた難治性慢性咳嗽治療剤としてのセロピタント剤の使用を評価する。セロピタント剤は小分子で高度に選択的なNK1-R拮抗剤である。同社は1日1回経口錠剤療法としてのセロピタントの開発を行う。同社はアトピー性皮膚炎に関連する掻痒症の第II相臨床試験を行う。   メンロ―・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。臨床段階で、主に皮膚疾患に対する治療薬の開発・製品化に従事する。同社の候補薬はアトピ―性皮膚炎、乾癬、結節性痒疹などの皮膚疾患による掻痒や、難治性・慢性咳嗽の治療のためのニュ―ロキニン1(NK-1)受容体アンタゴニストなどを含む。本社所在地はカリフォルニア州レッドウッドシティ。   Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
本社所在地 200 Cardinal Way 2nd Floor Redwood City CA 94063 USA
代表者氏名 Steven L. Basta スティーブンL.バスタ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-486-1416
設立年月日 40817
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.menlotherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/mnlo
adr_tso
EBITDA EBITDA(百万ドル) -40.19600
終値(lastsale) 6.14
時価総額(marketcap) 141084907.72
時価総額 時価総額(百万ドル) 129.82570
売上高 売上高(百万ドル) 14.32400
企業価値(EV) 企業価値(EV)(百万ドル) -23.92930
当期純利益 当期純利益(百万ドル) -31.45300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Menlo Therapeutics Inc revenues increased from $898K to $10.6M. Net loss increased 81% to $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $10.1M to $26.5M (expense) General and administrative increase from $2M to $5M (expense).

 MNLOのテクニカル分析


 MNLOのニュース

   This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth  2020/06/02 16:40:18 Yahoo Finance
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An
   Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%  2020/05/27 12:43:00 Zacks Investment Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
   Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates  2020/05/11 13:05:03 Zacks Investment Research
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
   Menlo (MNLO) in Focus: Stock Moves 9.9% Higher  2020/04/24 12:53:00 Zacks Investment Research
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
   Menlo (MNLO) in Focus: Stock Moves 9.9% Higher  2020/04/24 12:53:00 Zacks Investment Research
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.  2019/11/12 22:09:00 Benzinga Feeds
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX ) in connection with the proposed acquisition of the Company by Menlo Therapeutics, Inc. ("MNLO") (NASDAQ: MNLO ). Under the terms of the acquisition agreement, FOMX shareholders will receive 0.5924 shares of MNLO and a contingent stock right for each FOMX share they own. If you own FOMX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weisslawllp.com/foamix-pharmaceuticals-ltd/ Full story available on Benzinga.com
   Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study  2019/09/25 17:18:00 Zacks Investment Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.  2019/11/12 22:09:00 Benzinga Feeds
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX ) in connection with the proposed acquisition of the Company by Menlo Therapeutics, Inc. ("MNLO") (NASDAQ: MNLO ). Under the terms of the acquisition agreement, FOMX shareholders will receive 0.5924 shares of MNLO and a contingent stock right for each FOMX share they own. If you own FOMX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weisslawllp.com/foamix-pharmaceuticals-ltd/ Full story available on Benzinga.com
   Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study  2019/09/25 17:18:00 Zacks Investment Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   Menlo Therapeutics Offers A Low-Cap Biotech Opportunity With High Potential  2019/05/29 21:36:25 Seeking Alpha
   Menlo Therapeutics misses by $0.01  2019/05/02 20:56:08 Seeking Alpha
Menlo Therapeutics (MNLO): Q1 GAAP EPS of -$0.81 misses by $0.01. Cash, cash equivalents and investments of $121.52M Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メンロ―・セラピュ―ティクス MNLO Menlo Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)